PURPOSE: Functional imaging biomarkers of cancer treatment response offer the potential for early determination of outcome through the assessment of biochemical, physiologic, and microenvironmental readouts. Cell death may result in an immunologic response, thus complicating the interpretation of biomarker readouts. This study evaluated the temporal effect of treatment-associated inflammatory activity on diffusion magnetic resonance imaging and 2-[(18)F]-fluoro-2-deoxy-D-glucose-positron emission tomography imaging (FDG-PET) biomarkers to delineate the effects of the inflammatory response on imaging readouts. EXPERIMENTAL DESIGN: Rats with intracerebral 9L gliosarcomas were separated into four groups consisting of control, an immunosuppressive agent dexamethasone (Dex), 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), and BCNU+Dex. Animals were imaged using diffusion-weighted magnetic resonance imaging and FDG-PET at 0, 3, and 7 days posttreatment. RESULTS: In the BCNU- and BCNU+Dex-treated animal groups, diffusion values increased progressively over the 7-day study period to approximately 23% over baseline. The FDG percentage change of standard uptake value decreased at day 3 (-30.9%) but increased over baseline levels at day 7 (+20.1%). FDG-PET of BCNU+Dex-treated animals were found to have percentage of standard uptake value reductions of -31.4% and -24.7% at days 3 and 7, respectively, following treatment. Activated macrophages were observed on day 7 in the BCNU treatment group with much fewer found in the BCNU+Dex group. CONCLUSIONS: Results revealed that treatment-associated inflammatory response following tumor therapy resulted in the accentuation of tumor diffusion response along with a corresponding increase in tumor FDG uptake due to the presence of glucose-consuming activated macrophages. The dynamics and magnitude of potential inflammatory response should be considered when interpreting imaging biomarker results.
PURPOSE: Functional imaging biomarkers of cancer treatment response offer the potential for early determination of outcome through the assessment of biochemical, physiologic, and microenvironmental readouts. Cell death may result in an immunologic response, thus complicating the interpretation of biomarker readouts. This study evaluated the temporal effect of treatment-associated inflammatory activity on diffusion magnetic resonance imaging and 2-[(18)F]-fluoro-2-deoxy-D-glucose-positron emission tomography imaging (FDG-PET) biomarkers to delineate the effects of the inflammatory response on imaging readouts. EXPERIMENTAL DESIGN:Rats with intracerebral 9L gliosarcomas were separated into four groups consisting of control, an immunosuppressive agent dexamethasone (Dex), 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), and BCNU+Dex. Animals were imaged using diffusion-weighted magnetic resonance imaging and FDG-PET at 0, 3, and 7 days posttreatment. RESULTS: In the BCNU- and BCNU+Dex-treated animal groups, diffusion values increased progressively over the 7-day study period to approximately 23% over baseline. The FDG percentage change of standard uptake value decreased at day 3 (-30.9%) but increased over baseline levels at day 7 (+20.1%). FDG-PET of BCNU+Dex-treated animals were found to have percentage of standard uptake value reductions of -31.4% and -24.7% at days 3 and 7, respectively, following treatment. Activated macrophages were observed on day 7 in the BCNU treatment group with much fewer found in the BCNU+Dex group. CONCLUSIONS: Results revealed that treatment-associated inflammatory response following tumor therapy resulted in the accentuation of tumor diffusion response along with a corresponding increase in tumorFDG uptake due to the presence of glucose-consuming activated macrophages. The dynamics and magnitude of potential inflammatory response should be considered when interpreting imaging biomarker results.
Authors: Kuei C Lee; Bradford A Moffat; Anne F Schott; Rachel Layman; Steven Ellingworth; Rebecca Juliar; Amjad P Khan; Mark Helvie; Charles R Meyer; Thomas L Chenevert; Alnawaz Rehemtulla; Brian D Ross Journal: Clin Cancer Res Date: 2007-01-15 Impact factor: 12.531
Authors: Victor D Schepkin; Kuei C Lee; Kyle Kuszpit; Mukilan Muthuswami; Timothy D Johnson; Thomas L Chenevert; Alnawaz Rehemtulla; Brian D Ross Journal: NMR Biomed Date: 2006-12 Impact factor: 4.044
Authors: L D Stegman; A Rehemtulla; D A Hamstra; D J Rice; S J Jonas; K L Stout; T L Chenevert; B D Ross Journal: Gene Ther Date: 2000-06 Impact factor: 5.250
Authors: U Roelcke; R G Blasberg; K von Ammon; S Hofer; P Vontobel; R P Maguire; E W Radü; R Herrmann; K L Leenders Journal: J Nucl Med Date: 1998-05 Impact factor: 10.057
Authors: B A Moffat; D E Hall; J Stojanovska; P J McConville; J B Moody; T L Chenevert; A Rehemtulla; B D Ross Journal: MAGMA Date: 2004-12-01 Impact factor: 2.310
Authors: Daniel A Hamstra; Thomas L Chenevert; Bradford A Moffat; Timothy D Johnson; Charles R Meyer; Suresh K Mukherji; Douglas J Quint; Stephen S Gebarski; Xiaoying Fan; Christina I Tsien; Theodore S Lawrence; Larry Junck; Alnawaz Rehemtulla; Brian D Ross Journal: Proc Natl Acad Sci U S A Date: 2005-11-02 Impact factor: 11.205
Authors: C S Brock; H Young; S M O'Reilly; J Matthews; S Osman; H Evans; E S Newlands; P M Price Journal: Br J Cancer Date: 2000-02 Impact factor: 7.640
Authors: Thomas S C Ng; James R Bading; Ryan Park; Hargun Sohi; Daniel Procissi; David Colcher; Peter S Conti; Simon R Cherry; Andrew A Raubitschek; Russell E Jacobs Journal: J Nucl Med Date: 2012-06-01 Impact factor: 10.057
Authors: Svetlana Balyasnikova; Johan Löfgren; Robin de Nijs; Yanna Zamogilnaya; Liselotte Højgaard; Barbara M Fischer Journal: Am J Nucl Med Mol Imaging Date: 2012-10-15
Authors: Thomas S C Ng; David Wert; Hargun Sohi; Daniel Procissi; David Colcher; Andrew A Raubitschek; Russell E Jacobs Journal: Clin Cancer Res Date: 2013-03-26 Impact factor: 12.531
Authors: Stefanie Galbán; Benjamin Lemasson; Terence M Williams; Fei Li; Kevin A Heist; Timothy D Johnson; Judith S Leopold; Thomas L Chenevert; Theodore S Lawrence; Alnawaz Rehemtulla; Tom Mikkelsen; Eric C Holland; Craig J Galbán; Brian D Ross Journal: PLoS One Date: 2012-04-20 Impact factor: 3.240